Abcuro

id 12331
name Abcuro
category_id 9
sector_or_kind Biotech / Pharma
sector_slug biotech_pharma
parent_category_id 1
parent_kind Operating Company
parent_kind_slug operating_company
classification_tier
classification_confidence
hq_city
hq_country US
description Abcuro raised $66M in Series D funding to advance ulviprubart in an inclusion body myositis trial. NEA participated in the round alongsid...
tenant_id 1